Skip to main content

Test Price

2,800 AED

✅ Home Collection Available

CDKN1B Gene Multiple Endocrine Neoplasia Type 4 (MEN4) Genetic Test in UAE | 2800 AED | DHA Compliance

Executive Summary & Core Metrics

  • Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS Processing.
  • Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (daily 8 AM to 11 PM).
  • Clinical Guidance: Telephonic Post-Test Clinical Guidance by a DHA-licensed Consultant Medical Geneticist covering result interpretation and hereditary risk.
  • Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731 (pre‑approval within 2 hours).

Test Overview & Methodology

This advanced DNA analysis uses Next-Generation Sequencing (NGS) to screen the entire coding region of the CDKN1B gene for germline mutations causative of Multiple Endocrine Neoplasia Type 4 (MEN4), a rare hereditary cancer syndrome. The assay detects point mutations, small insertions/deletions, and copy number variations with 99.9% sensitivity and specificity.

Feature Our Test (MENA4GeneDX) Standard Gene Panel
Precision >99.9% analytical sensitivity & specificity (NGS with confirmatory Sanger) 95–98% limited to hotspot regions
Methodology Full gene NGS + deletion/duplication analysis (MLPA backup) Targeted mutation screening only
Turnaround Time 3 to 4 Weeks (ISO‑certified cold‑chain logistics) 4 to 8 Weeks (commercial reference labs)
Clinical Support Tele‑guidance by DHA‑licensed Consultant Medical Geneticist Generic PDF report, no consultation

Physician Insight & Safety Protocols

"Genetic testing for MEN4 can reveal critical information about your lifelong risk of developing multiple endocrine tumors. Interpreting a CDKN1B variant requires correlation with your family pedigree, biochemical profile, and imaging results. I strongly recommend that you undergo pre-test genetic counselling to understand the implications fully. A positive result is a call to action for surveillance, not a diagnosis of active disease."

— Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403

Advisory on Medication and Test Interpretation

⚠ Medication & Treatment Advisory

Do not alter or discontinue any prescribed medications (including calcium-lowering agents, hormone replacement, or anticancer drugs) based solely on genetic risk information. This test evaluates hereditary predisposition; immediate therapy decisions must be guided by your treating physician.


Exclusion Criteria & Urgent Care Indicators

  • This test is designed for germline (hereditary) analysis using blood or buccal DNA; it is not validated for somatic tumour testing.
  • Not indicated for acute endocrine crises. Seek emergency care if you experience sudden severe headache, vision loss, palpitations, confusion, or severe hypercalcemia.
  • Red flags requiring immediate endocrinology evaluation: rapidly enlarging neck mass, unexplained pituitary MRI abnormalities, or intractable hypercalcemia.

Patient FAQ & Clinical Guidance

1. How accurate is the CDKN1B NGS test for diagnosing MEN4?

Our NGS assay achieves 99.9% diagnostic sensitivity for point mutations and copy number changes in CDKN1B, far exceeding traditional methods. Because we sequence the entire gene and use a complementary MLPA backup, false-negative rates are virtually eliminated. All positive variants are confirmed by Sanger sequencing at no extra cost, and the report includes ClinVar and ACMG classification.

2. Will my health insurance cover the 2800 AED cost for this test?

We verify direct billing eligibility within two hours via WhatsApp—most UAE insurers cover hereditary cancer risk testing when medically justified. Our team handles pre-approval with DHA-compliant documentation. If the test is not covered, we offer flexible payment options and a detailed medical necessity letter for reimbursement claims. Simply send your insurance card photo to +971 54 548 8731.

3. What preparation is required before giving a blood sample for the MEN4 DNA test?

Fasting is not necessary; however, a pre-test genetic counselling session to map your family pedigree is mandatory for accurate risk interpretation. We arrange a confidential 30‑minute tele‑counselling session with a certified genetic counsellor prior to sample collection. Bring a list of all diagnosed cancers in first‑ and second‑degree relatives. Sample collection is a simple 4‑ml blood draw or a painless finger‑prick on an FTA card.

UAE Regulatory & Data Privacy Adherence

This test is performed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is processed through ISO 27001‑certified pipelines with strict anonymity and encrypted storage. Our facility holds ISO 9001:2015 Certification INT/EGQ/2509DA/3139 and operates under DHA Facility License Number 1143.

Clinical & Logistical Metadata

Test Name CDKN1B Gene Multiple Endocrine Neoplasia Type 4 (MEN4) Genetic Test
Price (AED) 2,800
Turnaround Time 3 to 4 Weeks
Sample Type / Matrix Peripheral whole blood (4ml) or finger-prick dried blood spot (FTA card)
Methodology Used Next-Generation Sequencing (NGS) of full CDKN1B coding region with MLPA backup and Sanger confirmation
ICD-10-CM Code E31.29 (Other multiple endocrine neoplasia syndromes)
LOINC Code 104160-3
DHA Facility License & Laboratory Address DHA License: 1143 | DNA Labs UAE | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians